PCM
WX

Prelude Capital Management’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Prelude Capital Management’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-36,210
Closed -$1.56M – 1893
2015
Q3 		$1.56M Sell
36,210
-13,880
-28% -$586K 0.23% 109
2015
Q2 		$2.12M Buy
50,090
+35,000
+232% +$1.48M 0.3% 77
2015
Q1 		$585K Sell
15,090
-100
-0.7% -$3.85K 0.08% 296
2014
Q4 		$511K Buy
15,190
+3,100
+26% +$109K 0.07% 303
2014
Q3 		$423K Hold
12,090
– – 0.06% 430
2014
Q2 		$397K Sell
12,090
-4,100
-25% -$140K 0.05% 468
2014
Q1 		$597K Sell
16,190
-12,930
-44% -$475K 0.08% 334
2013
Q4 		$1.12M Buy
29,120
+8,500
+41% +$268K 0.18% 124
2013
Q3 		$565K Sell
20,620
-7,100
-26% -$168K 0.09% 266
2013
Q2 		$582K Buy
+27,720
New +$541K 0.12% 217

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Prelude Capital Management's WX Position: Q4 2015 in Review

Prelude Capital Management sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 36,210 shares — an estimated $1.56M sold.

Prelude Capital Management first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $2.12M in Q2 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Prelude Capital Management reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Prelude Capital Management sold 36,210 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $1.56M.
  • Prelude Capital Management first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • Prelude Capital Management's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $2.12M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Prelude Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.